ERBB2 and cancer: Genetic biomarkers can be applied across multiple cancer types, e.g., HER2 (ERBB2) amplification, and the first genetic biomarker to be used in a cancer agnostic approach was NTRK fusions (Neurotrophic tyrosine receptor kinase) [63].